Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||AZD9150 + Durvalumab + Paclitaxel|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|AZD9150||ISIS 481464|ISIS-STAT3rx|Danvatirsen||STAT3 Inhibitor 18||ISIS-STAT3rx (AZD9150) is an antisense oligonucleotide that inhibits translation of STAT3, which is often activated by receptor tyrosine kinases including FGFR, thereby preventing cell proliferation (NCI Drug Dictionary, PMID: 23935373).|
|Durvalumab||Imfinzi||MEDI4736||Immune Checkpoint Inhibitor 95 PD-L1/PD-1 antibody 63||Imfinzi (durvalumab) is a monoclonal antibody that binds to and inhibits PD-L1 (CD274), potentially resulting in increased immune response to tumors (PMID: 25943534, PMID: 28214651). Imfinzi (durvalumab) is FDA approved for use in patients with urothelial carcinoma and unresectable, stage III non-small cell lung cancer, and in combination with etoposide and carboplatin or cisplatin in patients with extensive stage small cell lung cancer (FDA.gov).|
|Paclitaxel||Taxol||7-Epipaclitaxel||Antimicrotubule Agent 12 BCL2 Family Inhibitor 6||Taxol (paclitaxel) binds to tubulin to inhibit microtubule disassembly, which results in decreased cell division, and also binds to the anti-apoptotic factor Bcl-2, promoting apoptosis (NCI Drug Dictionary).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT03742102||Phase Ib/II||Durvalumab + Oleclumab + Paclitaxel Durvalumab + Paclitaxel + Selumetinib AZD9150 + Durvalumab + Paclitaxel Durvalumab + Paclitaxel Capivasertib + Durvalumab + Paclitaxel||A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer. (BEGONIA)||Recruiting|